<DOC>
	<DOCNO>NCT03088254</DOCNO>
	<brief_summary>To evaluate efficacy safety co-administrated temisartan/amlodipine rosuvastatin subject dyslipidemia hypertension .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Telmisartan/Amlodipine/Rosuvastatin</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Dyslipidemia hypertesion msSBP &lt; 180 mmHg msDBP &lt; 110 mmHg LDLC ≤ 250 mg/dL Triglycerides &lt; 400 mg/dL At Visit 3 , BP difference SBP ≥20mmHg DBP ≥10mmHg CK normal range ≥ 2 time Uncontrolled primary hypothyroidism ( TSH normal range ≥ 1.5 time ) AST ALT ≥ 2 time Uncontrolled diabetes mellitus ( HbA1c≥9 % ) CLcr &lt; 30 mL/min/1.73m^2 K &gt; 5.5 mEq/L Other exclusion apply</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>